References

1.

KADCYLA Prescribing Information. Genentech, Inc. July 2016.

2.

Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347-356.

3.

Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med. 2013;368:2442]. N Engl J Med. 2012;367:1783-1791 and Supplementary Appendix.

4.

Hicks DG, Kulkarni S. Review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129:263-273.

5.

Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232:123-138.

6.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hassmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330-9336.

7.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed June 8, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

8.

Ray S, Bonthapally V, McMorrow D, Bonafede M, Landsman-Blumberg P. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. J Comp Eff Res. 2013;2(2):195-206.

9.

Data on file. Genentech, Inc.

10.

Therasse P; European Organisation for Research and Treatment of Cancer Data Center. Evaluation of response: new and standard criteria. Ann Oncol. 2002;13(suppl 4):127-129.

11.

RECIST. Version 1.1 Update. http://www.irrecist.com/recist/recist-comparative/01.html. Accessed April 19, 2017.

12.

Center for Drug Evaluation and Research. Clinical review—BLA 125427: Kadcyla (ado-trastuzumab emtansine) for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Accessdata.fda.gov Web site. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125427Orig1s000MedR.pdf. Completed: January 25, 2013. Accessed April 19, 2017.